2016; 2017; 2018 – Revised Code; Billable/Specific Code; POA Exempt

• Q82.2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM Q82.2 is a revised 2018 ICD-10-CM code that becomes effective on October 1, 2017.
• This is the American ICD-10-CM version of Q82.2 – other international versions of ICD-10 Q82.2 may differ.

Applicable To

• Congenital diffuse cutaneous mastocytosis
• Congenital maculopapular cutaneous mastocytosis
• Congenital urticaria pigmentosa

Type 1 Excludes

• cutaneous mastocytosis NOS (D47.01)
• diffuse cutaneous mastocytosis (with onset after newborn period) (D47.01)
• malignant mastocytosis (C96.2-)
• systemic mastocytosis (D47.02)

2016; 2017; 2018 – Deleted Code; 2018 – New Code; Non-Billable/Non-Specific Code

• D47.0 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. (SEE below)
• ICD-10-CM D47.0 is a new 2018 ICD-10-CM code that became effective on October 1, 2017.
• This is the American ICD-10-CM version of D47.0 – other international versions of ICD-10 D47.0 may differ.

Type 1 Excludes

• congenital cutaneous mastocytosis (Q82.2-)
• histiocytic neoplasms of uncertain behavior (D47.Z9)
• malignant mast cell neoplasm (C96.2-)

2018 – New Code; Billable/Specific Code

• D47.01 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM D47.01 is a new 2018 ICD-10-CM code that becomes effective on October 1, 2017.
• This is the American ICD-10-CM version of D47.01 – other international versions of ICD-10 D47.01 may differ.

Applicable To

• Diffuse cutaneous mastocytosis
• Maculopapular cutaneous mastocytosis
• Solitary mastocytoma
• Telangiectasia macularis eruptiva perstans
• Urticaria pigmentosa

Type 1 Excludes

• congenital (diffuse) (maculopapular) cutaneous mastocytosis (Q82.2)
• congenital urticaria pigmentosa (Q82.2)
• extracutaneous mastocytoma (D47.09)

2018 – New Code; Billable/Specific Code

• D47.02 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM D47.02 is a new 2018 ICD-10-CM code that becomes effective on October 1, 2017.
• This is the American ICD-10-CM version of D47.02 – other international versions of ICD-10 D47.02 may differ.

Applicable To

• Indolent systemic mastocytosis
• Isolated bone marrow mastocytosis
• Smoldering systemic mastocytosis
• Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)

2018 – New Code; Billable/Specific Code

• D47.09 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM D47.09 is a new 2018 ICD-10-CM code that became effective on October 1, 2017.
• This is the American ICD-10-CM version of D47.09 – other international versions of ICD-10 D47.09 may differ.

Applicable To

• Extracutaneous mastocytoma
• Mast cell tumor NOS
• Mastocytoma NOS
• Mastocytosis NOS

2016; 2017; 2018 – Deleted Code; 2018 – New Code; Non-Billable/Non-Specific Code

• C96.2 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. (SEE below)
• ICD-10-CM C96.2 is a new 2018 ICD-10-CM code that became effective on October 1, 2017.
• This is the American ICD-10-CM version of C96.2 – other international versions of ICD-10 C96.2 may differ.

2018 – New Code; Billable/Specific Code

• C96.21 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM C96.21 is a new 2018 ICD-10-CM code that becomes effective on October 1, 2017.
• This is the American ICD-10-CM version of C96.21 – other international versions of ICD-10 C96.21 may differ.

2018 – New Code; Billable/Specific Code

• C96.22 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM C96.22 is a new 2018 ICD-10-CM code that becomes effective on October 1, 2017.
• This is the American ICD-10-CM version of C96.22 – other international versions of ICD-10 C96.22 may differ.

2018 – New Code; Billable/Specific Code

• C96.20 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM C96.20 is a new 2018 ICD-10-CM code that became effective on October 1, 2017.
• This is the American ICD-10-CM version of C96.20 – other international versions of ICD-10 C96.20 may differ.

2018 – New Code; Billable/Specific Code

• C96.29 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• ICD-10-CM C96.29 is a new 2018 ICD-10-CM code that became effective on October 1, 2017.
• This is the American ICD-10-CM version of C96.29 – other international versions of ICD-10 C96.29 may differ.

2016; 2017; 2018; Non-Billable/Non-Specific Code

• C94.3 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. (SEE below)
• The 2018 edition of ICD-10-CM C94.3 became effective on October 1, 2017.
• This is the American ICD-10-CM version of C94.3 – other international versions of ICD-10 C94.3 may differ.

2016; 2017; 2018; Billable/Specific Code

• C94.31 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• The 2018 edition of ICD-10-CM C94.31 became effective on October 1, 2017.
• This is the American ICD-10-CM version of C94.31 – other international versions of ICD-10 C94.31 may differ

2016; 2017; 2018; Billable/Specific Code

• C94.32 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• The 2018 edition of ICD-10-CM C94.32 became effective on October 1, 2017.
• This is the American ICD-10-CM version of C94.32 – other international versions of ICD-10 C94.32 may differ.

2016; 2017; 2018; Billable/Specific Code

• C94.30 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
• The 2018 edition of ICD-10-CM C94.30 became effective on October 1, 2017.
• This is the American ICD-10-CM version of C94.30 – other international versions of ICD-10 C94.30 may differ.

Applicable To

• Mast cell leukemia with failed remission
• Mast cell leukemia NOS

2017 – New Code; 2018; Non-Billable/Non-Specific Code

• D89.4 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. (SEE below)
• The 2018 edition of ICD-10-CM D89.4 became effective on October 1, 2017.
• This is the American ICD-10-CM version of D89.4 – other international versions of ICD-10 D89.4 may differ.

• 40 Mast cell activation, unspecified
• 41 Monoclonal mast cell activation syndrome
• 42 Idiopathic mast cell activation syndrome
• 43 Secondary mast cell activation
• 49 Other mast cell activation disorder

Type 1 Excludes

• aggressive systemic mastocytosis (C96.21)
• congenital cutaneous mastocytosis (Q82.2)
• (non-congenital) cutaneous mastocytosis (D47.01)
• (indolent) systemic mastocytosis (D47.02)
• malignant mast cell neoplasm (C96.2-)
• malignant mastocytoma (C96.29)
• mast cell leukemia (C94.3-)
• mast cell sarcoma (C96.22)
• mastocytoma NOS (D47.09)
• other mast cell neoplasms of uncertain behavior (D47.09)
• systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)

The CDC has released an ICD-10 code for HaT. This achievement will enhance recognition of HaT and acknowledge the advancements being made in this newly identified gene duplicate. We look forward to better patient data for our understanding, and most importantly insurance coverage and overall improved patient care.